Screening for ROP. by Quinn, Graham & Gilbert, Clare
 COMMUNITY EYE HEALTH JOURNAL | VOLUME 30 | NUMBER 99 | 2017  57 
SCREENING
Why is screening needed?
Treatment for severe ROP is usually 
successful in preserving vision as long 
as treatment is given on time by an 
experienced ophthalmologist. The 
purpose of screening is to identify 
babies who need urgent treatment. 
How and where should 
screening be done?
Most screening for ROP is undertaken 
by an ophthalmologist, using indirect 
ophthalmoscopy (Figure 1). 
Babies who are in-patients in the neonatal unit must 
be screened in the unit. Babies who need further 
screening after discharge can be bought back to the 
unit for screening or they can be screened in the eye 
department.
Over the last few years, wide-field digital imaging 
systems, instead of indirect ophthalmoscopy, have 
also been used for screening. The retinal image can 
be captured by an ophthalmologist, a trained nurse, 
or a technician (Figure 2). However, an experienced 
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Screening for ROP
Screening babies for ROP 
is very important. Unless 
ROP is detected early and 
promptly treated, it can 
lead to blindness and 
permanent visual 
impairment. This article 
describes who to screen, 
when and where to screen, 
how to screen, and what 
to do next. 
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Figure 1 Ophthalmologist screening for ROP using indirect ophthalmoscopy
ophthalmologist must always be available to interpret 
the images.
The screening results for each eye must be classified 
according to the criteria set up by the International 
Committee for the Classification of ROP (see pp. 55–56). 
Which babies should be screened?
This is an important question. Which babies are at 
risk of severe ROP varies considerably. For example, 
in units where neonatal care is less than ideal, bigger, 
more mature babies can still develop severe ROP. 
Several countries have national guidelines indicating 
which babies should be screened. These usually 
include a combination of birth weight (BW) and 
gestational age (GA). Some countries, such as the 
United States of America, include additional 'sickness 
criteria' alongside BW and GA. In neonatal units 
providing very high quality care, only the most preterm 
babies are at risk of developing ROP and therefore 
need to be screened.
• In the United Kingdom, babies with BW of <1,250 g, 
or a GA of 31 weeks or less, must be screened. 
• In the United States of America, the screening 
criteria are a BW of 1,500 g or less, or a GA of 30 
weeks or less. Infants with a BW between 1,500 g 
and 2,000 g should also be screened if they have 
had an 'unstable clinical course.'
Figure 2 Screening using a RetCam, which uses a probe 
placed gently on the eye
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• In China, a middle-income country, the criteria are 
BW <2,000 g or GA <34 weeks. Compared with the 
UK and USA, older and bigger babies in China are 
considered to be at risk of developing ROP. 
Ideally, studies need to be done in each country to 
determine which babies should be included in a 
screening programme. 
Whichever criteria are used, it is the responsibility of 
the neonatologist to identify which babies should be 
screened, and a neonatal nurse should prepare the 
babies for screening (p. 54). 
When screening should start
Preterm babies are not born with ROP; it only develops 
during the first few weeks after birth. 
It is useful to have guidelines for the timing of the first 
screening which are easy to implement, particularly 
in settings where information on GA is unreliable. 
For example, screen by 30 days of life. If the baby is 
very premature, or has been very sick or received a 
lot of oxygen, earlier screening should be considered. 
Current thinking suggests screening between 21 and 
25 days of life, but more research is needed. If a baby 
eligible for screening is to be discharged or transferred 
to another neonatal unit before the first screening, 
they should be screened before discharge or transfer.
Understanding the findings of screening
• In eyes where the retinal blood vessels can only be 
seen in zone I at the first screening, about half will 
go on to develop ROP needing treatment. 
• If the retinal blood vessels have reached zone II 
at the first screening, ROP needing treatment is 
unlikely.
• If mature vessels can be seen in zone III, ROP 
needing treatment is rare. 
Making decisions
At each examination, a management decision needs 
to be made, based on the eye with the most advanced 
ROP (Figure 3).
The possible management decisions are: 
1 Urgent treatment.
2 Further screening is needed (see below).
3 No further screening is needed as the retinal blood 
vessels are mature, or ROP is regressing in both eyes. 
If urgent treatment is needed, this must be delivered 
within 48 to 72 hours. If further screening is needed, 
the date of the next screening examination must be 
documented and explained to parents. Figure 4 shows 
which babies need urgent treatment.
Repeat screening
Findings at the first examination determine when the 
next screening should take place. 
• If the retinal vessels are immature and there is 
no ROP, follow-up screening can be conducted 
1–2 weeks later.
• If there is Stage 1 ROP in zone II with no plus 
disease, repeat screening in 1 week.
• If there is Stage 2 ROP in zone II with plus disease, 
urgent treatment is needed.
Documenting and communicating 
findings and management decisions
It is very important that accurate records are kept 
for all babies who have been screened for ROP. This 
will help to ensure that babies are screened at the 
right time and that follow-up screening is done as 
and when needed. If a baby is not screened when 
they should have been, they are more likely to 
become visually impaired or blind. At each screening, 
document all findings for both eyes (immature 
retinal vessels, stage, zone, plus disease, aggressive 
posterior, ROP is regressing). Note whether treatment 
or further screening is needed, and when. 
Finally, ensure that all information is shared with the 
neonatal team and the parents. ROP is a complex 
disease with long-term consequences and requires a 
team effort (see pp. 60–61).
Figure 4 Indications for urgent treatment from the Early Treatment of ROP Trial
Stage 1 Stage 2 Stage 3
Zone I No plus disease
With plus disease
Zone II No plus disease
With plus disease
Zone 
III
No plus disease
With plus disease
Aggressive posterior ROP
Urgent treatment 
(within 48–72 hours)
Repeat 
screening
Figure 3 Screening options for ROP and the information to be documented 
and communicated
Screening by a trained 
neonatal nurse or 
trained technician using 
wide-field digital imaging
Images accessed 
and assessed by an 
ophthalmologist with 
expertise in ROP
No further 
screening
Further 
screening 
arranged
Urgent 
treatment 
within 48–72 
hours
Management decision:
1. Urgent treatment needed in one or both eyes
2. Screen again in 3–14 days
3. Further screening no longer required: mature 
    retinal vessels or ROP definitely regressing
Screening by an 
ophthalmologist using 
indirect ophthalmoscopy
Document all findings for 
both eyes (Stage, zone, plus 
disease) in medical records
Clearly communicate 
findings to the neonatal 
team and parents/carers
Document the management 
decision in medical records. 
Clearly communicate the 
decision to the neonatal 
team and parents/carers
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